Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIG and Nucleoside Analogues?

Annals of Hepatology

Volumn 10, Issue 2, 2011, Pages 180-187

  Campos Varela, Isabel ^a,c,d   Castells, Lluís ^a,c,d   Buti, María ^a,c,d   Vargas, Víctor ^a,c,d   Bilbao, Itxarone ^b,c,d   Rodríguez Frías, Francisco ^a,c   Jardí, Rosendo ^a,c   Charco, Ramón ^b   Guardia, Jaime ^a,c,d   Esteban, Rafael ^a,c,d  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

HBV real time PCR; HBV recurrence; Liver transplantation; Prophylaxis regimen

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; CYCLOSPORIN; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE DERIVATIVE; STEROID; TACROLIMUS; TENOFOVIR DISOPROXIL; VIRUS DNA;

ACUTE GRAFT REJECTION; ACUTE HEPATITIS; ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HEPATITIS B; HUMAN; INFECTION PREVENTION; INFECTION RISK; LIVER GRAFT; LIVER GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREOPERATIVE EVALUATION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT INFECTION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; VIRUS LOAD;

EID: 79956056364     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31567-4     Document Type: Article

References (39)

1. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. New Engl J Med 1993; 329: 1842-7.
2. Devlin J, Smith HM, O'Grady JG, et al. Impact of immuno-prophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients. J Hepatol 1994; 21: 204-10.
3. Roche B, Samuel D. Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results. J Hepatol 2003; S181-S189.
4. Marzano A. The prevention of viral recurrence in the long term. Dig Liver Dis 2009; 41(Suppl.)2: S195-S197.
5. Saab S, Yam MY, Stone MA, et al. Decision analisis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl 2009; 15: 413-20.
6. Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention fo hepatits B recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-10.
7. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-9.
8. Grellier L, Multimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-1215.
9. Grellier L, Dusheiko GM. Hepatitis B virus and liver transplantation: concepts in antiviral prophylaxis. J Viral He-pat 1997; 4(Suppl. 1): 111-6.
10. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-95.
11. Buti M, Castells L, Campos I, et al. Prevention of HBV recurrence after liver transplant: The role of combination therapy. Dig Liver Dis 2009; 4 (Suppl. 3): S98-S103.
12. Roche B, Feray C, Gigou M et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003; 38: 86-95.
13. Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepa-tol 2003; 38: 811-17.
14. Buti M, Mas A, Prieto M, et al. Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of he patitis B virus recurrence. Transplantation 2007; 84: 650-4.
15. Marzano A, Gaia S, Ghisetti V, et al. Viral Load at the Time of Liver Transplantation and Risk of Hepatitis B Virus Recurrence. Liver Transpl 2005; 11: 402-9.
16. Beckebaum S, Sotiropoulos GC, Klein CG, et al. Predictive Factors of Outcome in Patients Transplanted for Hepatitis B. Transplantation 2009; 87: 872-81.
17. Marzano A, Ciancio A, Salizzoni M, et al. Hepatitis B virus subtypes and lamivudine resistance. Lancet 2001; 358: 153-4.
18. Marzano A, Lampertico P, Mazzaferro V, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 532-8.
19. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419-27.
20. Peters MG, Singer G, Howard T, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68: 1912-14.
21. Seehofer D, Rayes N, Steinmuller T, et al. Liver transplantation in hepatitis B patients with preoperative resistance formation during lamivudine treatment. Transplant Proc 2002; 34: 2274-5.
22. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-2.
23. de-Man RA, Bartholomeusz AI, Niesters HG, et al. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J He-patol 1998; 29: 669-75.
24. Lerut JP, Donataccio M, Ciccarelli O, et al. Liver transplantation and HBsAg positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the signi?cant determinants of long-term prognosis. J He-patol 1999; 30: 706-14.
25. Samuel D, Zignego AL, Reynes M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21: 333-9.
26. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, et al. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29(9): 1294-305.
27. Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transplant 2008; 14: S15-S22.
28. Steinmüller T, Seehofer D, Rayes N, et al. Increasing Applicability of Liver Transplantation for Patients With Hepatitis B- Related Liver Disease. Hepatology 2002; 35: 1528-35.
29. Shi-Bin Xie, Jian-Yun Zhu, Zhang Ying, et al. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 Cases Follow-Up Study. Transplantation 2010; 90: 786-90.
30. Jardi R, Rodríguez F, Buti M, et al. Quantitative detection of hepatitis B virus DNA in serum by a rapid real- time fluorescence PCR assay. J Viral Hepat 2001; 8: 465-71.
31. Faust D, Rabenau HF, Allwinn R, et al. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobu-lin to prevent reinfection after orthotopic liver transplantation. Clin Transplant 2003; 17(3): 254-8.
32. Han SH, Martin P, Edelstein M, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9(2): 182-7.
33. Castells L, Campos-Varela I, Buti M, et al. Pharmacokinetics of intramuscular and intravenous HBIg: Which implications for practice? Dig Liver Dis 2009; 4(Suppl. 3): S119-S123.
34. Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-26.
35. Neff GW, O'Brien CB, Nery J, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004; 10: 1372-8.
36. McCaughan GW, Spencer J, Koorey D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transplant Surg 1999; 5: 512-19.
37. Faria LC, Gigou M, Roque-Afonso AM, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B recurrence after liver transplantation. Gastroente-rology 2008; 134: 1890-1899.
38. Saab S, Yeganen M, Nguyen K, et al. Recuurence of hepa-tocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Liver Transpl 2009; 15: 1525-34.
39. Wong DK, Yuen MF, Poon RT, et al. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol 2006; 45: 553-9.